Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Shares rose after a jump in sales of the blockbuster Dupixent drug and robust pharmaceutical launches delivered higher ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...

France's Sanofi reported a third-quarter profit that beat analysts' expectations on Friday, boosted by strong demand for its ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...

Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.

Sanofi posted strong Q3 results amid currency challenges; discover key pipeline updates and growth prospects for investors.

Discover Regeneron’s Q3 2025 earnings: strong Dupixent, Libtayo & EYLEA HD growth, R&D updates, plus key manufacturing and regulatory challenges.

Dupixent’s Q3 sales increased by 26.2%, breaking through the €4bn ceiling for the first time in a single quarter.

Sanofi SNY reported third-quarter 2025 adjusted earnings of $1.70 per American depositary share, which beat the Zacks ...

Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the ...